Collectively, these preclinical findings establish strong proof-of-concept for an AAV9-mediated gene regulation therapy that targets GABAergic inhibitory neurons to address the underlying cellular and genetic mechanism of SCN1A+ DS. The gene discussed is SCN1A; the disease is Dravet syndrome.